| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2015: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Outline of Final Research Achievements |
We evaluated the expression of FcγRIIB on B cell subsets in systemic sclerosis (SSc). The expressions of FcγRIIB on SSc naïve B cells and double negative (DN) memory B cells were significantly elevated than that on B cells of healthy subjects. Patients with the elavated expression of FcγRIIB on DN memory B cells more frequently had interstitial lung disease than those with normal levels. In bleomycin-induced fibrosis model, fibrosis was singnificanlty worsened in FcγRIIB-deficient mice compared to wild-type mice. Our results suggest that SSc B cells exhibit compensatory increases in the expression of FcγRIIB in order to suppress the abnormal activation of B cells, and the expression of FcγRIIB may be an indicator of the clinical severity of SSc.
|
